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1.3% was observed (p< 0.001). For VAS-identified adherent patients, CVR decreased 
significantly by 4.4% from baseline to 90 days (p< 0.001). However, a significant 
decrease of 4.3% (p< 0.001) was also observed for VAS-identified non-adherent 
patients. ConClusions: Patients identified as adherent using the first item of 
the BAAS showed significantly improved 10-year cardiovascular risk scores after 
90 days of treatment with valsartan, compared to patients who were identified as 
non-adherent. The VAS scale was not sufficiently sensitive to determine the effect 
of adherence on cardiovascular risk score.
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objeCtives: Patients with Atrial fibrillation (AF), have a five-fold increase in 
the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K 
antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel 
oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was 
unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism 
reduction without impacting the risk of major bleeding or intracranial hemorrhage. 
Patient characteristics of the Latin America (LA) cohort and overall population are 
presented. Methods: Patients with AF at an increased risk for stroke and whom 
VKA therapy was unsuitable were randomized to receive apixaban (5 mg twice 
daily) or aspirin (81 to 324 mg) in a double blind trial. The study recruited from 36 
countries from September 2007 through December 2009. Five countries were from 
LA: Argentina, Brazil, Chile, Colombia, and Mexico. Patient characteristics from the 
LA cohort, is presented relative to the overall trial population. Results: Of5599 
patients in the trial, 1185 were from LA (21.2%). Mean age was similar, 71.5 and 70 
for LA and overall cohort respectively. 55% and 58% were males for LA and overall 
cohort respectively. The LA and overall cohorts had similar rates of prior stroke or 
TIA, diabetes mellitus and hypertension receiving treatment, at enrollment. Mean 
CHADS2 score at enrollment was 2,.0 for the apixaban arm and 2.1 for the ASA arm, 
which is the same for cohorts. Other baseline characteristics were similar. Region 
subgroup analysis revealed no statistically significant (p> 01.0) interactions between 
treatment effects and geographic region. ConClusions: Baseline demographic and 
disease characteristics data from the LA cohort were similar to that of the clinical 
trial population. Results, in terms of safety and efficacy, given the total population 
trial, are expected to be consistent since interaction between treatment effects and 
geography was not significant.
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objeCtives: To examine the initiation of oral antihyperglycemic agents (OAHAs) 
and/or statins in patients with type 2 diabetes mellitus (T2DM) and assess the time 
elapsed from diagnosis to treatment initiation and intensification when goals were 
not achieved in real world practice. Methods: A retrospective study was performed 
on 662 medical records of patients with T2DM, diagnosed 24 to 48 months prior to 
signing the informed consent. The study included thirty-one general practitioner/
specialist sites across Mexico, Argentina and Brazil. Inclusion criteria: age ≥ 21 years 
at diagnosis; complete record of pre-diagnosis medication and pre-existing CV risk 
factors and 2 years follow-up records. Exclusion criteria: type 1 diabetes; pregnancy; 
receiving antihyperglycemic agents or statins prior to diagnosis; initially treated 
with insulin after T2DM diagnosis; or clinical trial participation during the study 
period. Descriptive statistics were used for demographic/clinical characteristics. 
Kaplan-Meier test was used to examine time to treatment and cumulative treat-
ment probability and multivariate logistic regression examined factors associated 
with such treatment. Results: At diagnosis, patients had a mean age of 53 years; 
44% had hypertension, 42% were obese and 23% had hypercholesterolemia. During 
the 2-year follow-up period, 93% were treated with OAHAs but only 29% of those 
eligible for statin therapy received statins. Time elapsed before first prescription of 
OAHA was 59±141 (Mean±SD) and 1 (1, 31) (median [IQR]) days and 230±232 days and 
132 (30, 406) days for statin. No variables were associated with OAHA initiation but 
family history of T2DM and hypercholesterolemia at diagnosis were associated with 
statin initiation. No antihyperglycemic treatment intensification was recorded in 
51%/53% of patients with HbA1c/FPG values above treatment targets during the fol-
low-up period. ConClusions: The delay in treatment of hypercholesterolemia and 
intensification of treatment for hyperglycemia in patients with T2DM not attain-
ing treatment targets works against effective prevention of chronic complications.
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intRoduCtion: Diabetes Mellitus (DM) is characterized by the high level of blood 
glucose. Ministry of Health data estimated that Brazil had about 10 million DM cases 
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objeCtives: Estimate the expenditure in hospital services for cardio-vascular 
(CVD), malignant tumors (MT) and diabetes financed by Seguro Popular (SP) for 2004-
2012 in order to evaluate its midterm financial sustainability. Methods: Hospital 
costs for interventions financed by SP for year 2012. Related hospital discharges 
from the SAEH for 2004-2012. Multiplication of both data generated the cost per 
ICD-10. The product was then grouped by GBD. Total hospital expenditure for SP, 
obtained from SINAIS for 2004-2012, was distributed using the cost per GBD. Then 
the proportion of hospital expenditure related to CVD, MT and diabetes is esti-
mated. Results: Mexico is one of the countries with the highest prevalence of child 
and adult overweight and obesity (O&O). That situation imposes a great pressure 
into SP to face an increasing demand of health care for non-communicable chronic 
diseases (NCD) particularly diabetes, MT and CVD. The average annual hospital 
expenditure of these groups of diseases represents about USD$273.4 million in 2012 
(9.7% of hospital expenditure). Malignant tumors that contributed the most were 
breast and cervical cancer with 90% of the total expenditure for this group. Acute 
myocardial infarction represents 66% of total expenditure for cardio-vascular. Under 
the status quo an increase of 65% in the cost of this group of diseases is expected 
for 2018. ConClusions: Findings show an increased financial burden for SP gen-
erated by the selected NCD. The impact on the public budget that represents this 
level of hospital expenditure would threaten the sustainability of the SP if current 
trends hold. Given the demographic transition and level of O&O as risk factors for 
developing NCD in the coming years it is necessary to strengthen prevention and 
health promotion to reduce both new cases of NCD and complications in order to 
decrease their future impact on the SP budget.
bi4
hospitAlizAtion Costs oF type 2 diAbetes mellitus (t2dm) pAtients in 
A publiC hospitAl in brAzil
Saad R1, Piedade A2, Wiens A1, Baptista DR1, Pontarolo R1
1Universidade Federal do Paraná, Curitiba, Brazil, 2Evidências - Kantar Health, Campinas, Brazil
objeCtives: Diabetes is considered an outpatient care condition, manageable in 
the primary care setting, but which complications may lead to hospitalization. There 
is limited data on the costs of patients hospitalized due to diabetes in Brazil. We 
aimed to estimate the percentage of type-2 diabetes mellitus (T2DM) patients who 
were hospitalized and the mean cost per hospitalization within a public hospital in 
Brazil (SUS). Methods: T2DM outpatients followed at the Hospital das Clínicas of 
Universidade Federal do Paraná (HC-UFPR) between 2011 and 2014 were eligible. Data 
from the last year of treatment were collected and validated within medical charts. 
We assessed demographics, hospitalization and cause, length and average costs 
per day of hospitalization. Exchange rate was 1.00USD = 3.21BRL. The study was 
approved by HC-UFPR IRB. Results: A total of 728 patients with T2DM were evalu-
ated, of which 38 (5.2%, 22 females and 17 males) were hospitalized due to eight dif-
ferent causes. Mean age was 64 years (44 to 84). Main reason for hospitalization was 
cardiovascular related problems (58.5%), followed by decompensated diabetes treat-
ment (17.0%) and kidney problems (9.4%). Average daily cost ranged from 907BRL 
(~283USD) (Neurology Center) to 2218BRL (~691USD) (Intensive Cardiology Therapy 
Center). The amount spent on the Cardiology Center represented 27.5% (188,244BRL) 
(~58,643USD) of the total, followed by Intensive Cardiology Therapy Center with 
18.1% (124,189BRL) (~38,688USD). Total hospital spending with 38 hospitalizations 
was 685,058BRL (~213,414USD) and mean length of hospitalization was 10 days 
(1 to 30 days). Mean cost per patient was 18,028BRL (~5,616USD). ConClusions: 
Hospitalized patients with T2DM represent a significant burden to healthcare pay-
ers. However, the amount spent by the hospital is not necessarily the same reim-
bursed by the Brazilian Public Healthcare System (SUS), which hinders the estimate 
of the burden for the system as a whole.
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objeCtives: In patients with hypertension, non-adherence to prescribed treatment 
may contribute to a significant increase in cardiovascular risk. The aims of this 
study were (1) to examine if two single-item physician-administered adherence 
scales are predictive of cardiovascular risk and (2) to evaluate whether adherence 
to antihypertensive medications is associated with at least a one percent reduction 
in cardiovascular risk over 90 days. Methods: Pooling data from seven observa-
tional studies, this analysis included 8,438 hypertensive patients taking valsartan. 
A ten-year cardiovascular risk (CVR) score was estimated following the risk scoring 
system proposed by the SCORE project in Europe. CVR score considered the following 
variables: age, total cholesterol, current smoking status, systolic blood pressure, and 
sex. At baseline and 90 days, physicians administered two single-item measures of 
adherence: the first item of the Basel Assessment of Adherence Scale (BAAS) and the 
Visual Analogue Scale (VAS). Results: At 90 days, males (4,257) had a significantly 
higher CVR than females (4,091) (p< 0.001). For BAAS-identified adherent patients, 
CVR decreased significantly by 2.6% from baseline to 90 days (p-value< 0.001). For 
BAAS-identified non-adherent patients, a significant but smaller decrease in CVR of 
